查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086090

多發性硬化症市場：2026-2032年全球市場預測（按類型、治療方法、作用機制、給藥途徑、藥物類型和最終用戶分類）

Multiple Sclerosis Market by Multiple Sclerosis Type, Treatment Type, Mechanism of Action, Route of Administration, Drug Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，多發性硬化症市場將成長至 583.4 億美元，複合年成長率為 8.29%。

主要市場統計數據
基準年 2025 334億美元
預計年份：2026年 361.1億美元
預測年份 2032 583.4億美元
複合年成長率 (%) 8.29%

多發性硬化症（MS）是一種慢性免疫介導的中樞神經系統疾病，會影響大腦、脊髓和視神經。根據多發性硬化症圖譜（MS Atlas）的數據，全球約有280萬人患有MS，大多數患者在青年時期確診，女性患病率約為男性的兩倍。鑑於這些流行病學事實，MS的治療在疾病修正治療、復發管理、神經保護研究、復健和長期照護協調等方面都屬於優先研究領域。

對於製藥和生物技術行業的領導者而言，多發性硬化症 (MS) 市場的發展受到以下因素的影響：高效療法的持續推廣、生物標記和 MRI 監測的日益普及，以及在真實世界患者群體中證明療效持續性的壓力不斷增加。如今，經營團隊的決策依賴於將臨床療效、安全性、用藥依從性、患者可及性以及面向保險公司的證據整合到一個統一的 MS 商業化策略中。

多發性硬化症（MS）治療格局的變革性變化

多發性硬化症 (MS) 的治療格局正在轉變，從延遲逐步強化治療的策略轉向對合適的患者儘早引入高效的疾病修正治療。有證據表明，早期控制發炎可以減少復發活動和 MRI 上的病灶積累，這為上述轉變提供了支持。雖然單株抗體、S1P 受體調變器、富馬酸鹽、抗 CD20 療法和免疫重建療法等治療選擇不斷增加，但個人化風險獲益評估的需求也日益成長。

人工智慧對多發性硬化症（MS）的累積影響

人工智慧 (AI) 對多發性硬化症 (MS) 的研究、診斷、臨床試驗設計以及上市後證據的產生正產生日益顯著的影響。 AI 驅動的磁振造影 (MRI) 分析有助於病灶檢測、病灶體積測量、腦萎縮評估和縱向比較，從而幫助臨床醫生和研究人員減輕 MS 監測帶來的繁重影像檢查負擔。這些工具只有在與神經放射學專家的工作流程檢驗並整合到臨床實踐中後，才能發揮其最大價值。

MS市場關鍵區域洞察

北美，尤其是美國和加拿大，憑藉其高診斷率、先進的神經系統基礎設施、健全的保險報銷體係以及專業療法的快速普及，在多發性硬化症（MS）市場持續佔據主導地位。歐洲也擁有成熟的MS診療環境，這得益於其國家醫療保健體系、MS登記系統、學術神經系統網路、醫療技術評估流程以及主要經濟體中疾病修正治療的建立。

針對多發性硬化症相關人員的關鍵群體洞察

儘管東協地區的MS診斷率仍然相對較低，但隨著新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國的三級醫療機構、MRI基礎設施和神經科培訓計畫的改善，該市場正在蓬勃發展。海灣合作理事會（GCC）國家受益於醫療保健領域的大量投資和專科醫療服務的普及，這為建立一流的MS治療中心、靜脈輸液治療服務和系統性的患者支持計畫創造了機會。

多發性硬化症的關鍵國家概況

美國是多發性硬化症治療領域最大的商業性市場，這得益於特效藥的推出、臨床試驗的積極參與以及神經系統亞專科藥物的廣泛應用，但價格承受能力和支付方的控制權仍然是影響市場的主要因素。加拿大是世界上多發性硬化症報告中患病率最高的國家之一，並擁有完善的登記系統。同時，墨西哥和巴西正透過公共和私人管道擴大治療覆蓋範圍，但在預算和地區層面仍存在差異。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠展現持續臨床價值的實證策略，這些策略不僅應關注復發預防，還應涵蓋殘疾進展、認知功能、疲勞、MRI觀察、腦容量減少、藥物依從性和患者報告結局等因素。鑑於成熟治療領域（特別是生物相似藥和學名藥領域）的價格壓力日益增大，市場進入團隊需要儘早與支付方就療效比較、預算影響和實際使用率達成一致。

調查方法

本執行摘要基於對已驗證的二手資料的系統性回顧，包括全球多發性硬化症 (MS) 流行病學參考文獻、監管公告、同行評審的臨床文獻、衛生技術評估趨勢、最新臨床二級資訊來源以及知名神經病學和 MS 組織發布的信息。檢驗重點關注數據的一致性、臨床相關性以及在治療、診斷、地理位置和可近性方面的市場適用性。

結論

多發性硬化症 (MS) 市場正朝著早期療育、高效治療、精準監測和更廣泛的證據要求方向發展。雖然疾病修正治療已改善了許多患者的預後，但在疾病進行性、殘疾預防、認知障礙、疲勞、公平獲取以及最佳化長期安全性等領域，仍存在許多未被滿足的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 多發性硬化症市場：以多發性硬化症類型分類

  • 原發性的
  • 次發性
  • 復發型
  • 進行性復發型

第8章 多發性硬化症市場：依治療類型分類

  • 疾病修正治療
    • 注射藥物
    • 口服藥物
    • 單株抗體
  • 症狀治療
  • 急性復發的處理

第9章 多發性硬化症市場：依作用機轉分類

  • 免疫調節劑
  • 免疫抑制劑
  • 細胞消融療法
  • S1P受體調變器
  • 抗黏附分子

第10章 多發性硬化症市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 靜脈

第11章 多發性硬化症市場：依藥物類型分類

  • 生物製劑
  • 低分子化合物

第12章 多發性硬化症市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 居家照護環境

第13章 多發性硬化症市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 多發性硬化症市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 多發性硬化症市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Horizon Therapeutics plc
  • Johnson & Johnson
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics, Inc.
  • UCB SA
  • Viela Bio, Inc.
Product Code: MRR-036C5CF3A89D

The Multiple Sclerosis Market is projected to grow by USD 58.34 billion at a CAGR of 8.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 33.40 billion
Estimated Year [2026] USD 36.11 billion
Forecast Year [2032] USD 58.34 billion
CAGR (%) 8.29%

Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system that affects the brain, spinal cord, and optic nerves. According to the Atlas of MS, approximately 2.8 million people live with MS worldwide, with diagnosis most often occurring in early adulthood and women affected about twice as often as men. These epidemiological realities make MS a high-priority therapeutic area for disease-modifying therapies, relapse management, neuroprotection research, rehabilitation, and long-term care coordination.

For pharmaceutical and biotechnology leaders, the multiple sclerosis market is shaped by the continued expansion of high-efficacy therapies, growing use of biomarkers and MRI monitoring, and increasing pressure to demonstrate durable outcomes in real-world populations. Executive decision-making now depends on integrating clinical efficacy, safety, adherence, patient access, and payer evidence into a unified MS commercialization strategy.

Transformative Shifts in the MS Landscape

The MS treatment landscape has shifted from delayed escalation toward earlier use of higher-efficacy disease-modifying therapies in appropriate patients, supported by evidence that early inflammatory control can reduce relapse activity and MRI lesion accumulation. Monoclonal antibodies, S1P receptor modulators, fumarates, anti-CD20 therapies, and immune reconstitution approaches have expanded treatment choice while increasing the need for individualized risk-benefit assessment.

Another major shift is the growing emphasis on progressive MS, disability accumulation independent of relapse activity, and patient-reported outcomes. Stakeholders are moving beyond annualized relapse rate alone and focusing on confirmed disability progression, cognition, fatigue, mobility, treatment persistence, and quality of life. This transformation is intensifying investment in biomarkers, longitudinal registries, and therapies that address neurodegeneration as well as inflammation.

Cumulative Impact of Artificial Intelligence in MS

Artificial intelligence is increasingly influencing MS research, diagnosis, clinical trial design, and post-market evidence generation. AI-assisted MRI analysis can support lesion detection, lesion volume measurement, brain atrophy assessment, and longitudinal comparison, helping clinicians and researchers manage the high imaging burden associated with MS monitoring. These tools are most valuable when validated against expert neuroradiology workflows and integrated with clinical context.

In drug development, machine learning is being applied to patient stratification, endpoint enrichment, digital biomarkers, and real-world evidence analytics. AI can help identify progression patterns, predict relapse risk, and improve trial efficiency, but its cumulative impact depends on transparent algorithms, diverse datasets, regulatory-grade validation, privacy safeguards, and avoidance of bias across sex, ethnicity, geography, and disability status.

Key Regional Insights Across the MS Market

North America remains a leading MS market due to high diagnosis rates, advanced neurology infrastructure, strong reimbursement pathways, and rapid adoption of specialty therapies, particularly in the United States and Canada. Europe also represents a mature MS environment, supported by national health systems, MS registries, academic neurology networks, health technology assessment processes, and established use of disease-modifying therapies across major economies.

Asia-Pacific is expanding as awareness, MRI availability, specialty neurology access, and healthcare spending rise, although prevalence and diagnosis patterns vary substantially across China, Japan, South Korea, India, Australia, and ASEAN markets. Latin America shows improving access in Brazil, Mexico, and other larger systems, but affordability and uneven specialist coverage remain constraints. The Middle East is strengthening tertiary care and specialty pharmacy channels, particularly in GCC countries, while Africa faces underdiagnosis, limited MRI access, and significant treatment access gaps despite rising recognition of MS across urban centers.

Key Group Insights for MS Stakeholders

Within ASEAN, MS remains comparatively underdiagnosed, but the market is developing as tertiary hospitals, MRI capacity, and neurologist training improve in countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries benefit from high healthcare investment and expanding specialty medicine access, creating opportunities for MS centers of excellence, infusion services, and structured patient support programs.

The European Union is central to MS evidence generation, regulatory harmonization, pharmacovigilance, and long-term registry-based research, while BRICS economies combine large patient populations with uneven reimbursement and access maturity across Brazil, Russia, India, China, and South Africa. G7 countries continue to influence global MS treatment standards through clinical trial leadership, payer scrutiny, and adoption of high-efficacy therapies. NATO members overlap significantly with high-income MS markets, where security of pharmaceutical supply chains, data governance, and health system resilience are increasingly relevant to sustained access.

Key Country Insights in Multiple Sclerosis

The United States is the largest commercial opportunity for MS therapies, driven by specialty drug adoption, active clinical trial participation, and broad availability of neurologic subspecialty care, although affordability and payer management remain major market-shaping factors. Canada has among the world's highest reported MS prevalence and strong registry infrastructure, while Mexico and Brazil are expanding access through public and private channels but face budget and regional access disparities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature MS treatment pathways, with Germany often serving as an early-adoption market and the UK emphasizing health technology assessment and evidence-based access. Russia has a sizable MS population but faces procurement and access variability. In Asia-Pacific, China and India offer long-term development potential as diagnosis improves, Japan and South Korea provide advanced specialty care and established neurology networks, and Australia has high MS awareness, strong clinical networks, and structured reimbursement for approved therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence strategies that show durable clinical value beyond relapse reduction, including disability progression, cognition, fatigue, MRI activity, brain volume loss, adherence, and patient-reported outcomes. Market access teams should align early with payers on comparative effectiveness, budget impact, and real-world persistence, particularly as biosimilars and generics intensify pricing pressure in established therapy classes.

Organizations should also strengthen patient support, safety monitoring, and treatment navigation to improve adherence and continuity of care. High-priority opportunities include progressive MS, remyelination, neuroprotection, digital monitoring, biomarker-guided therapy selection, and AI-enabled trial optimization. Partnerships with MS registries, academic centers, imaging networks, and advocacy organizations can improve data quality, support equitable access, and accelerate patient-centered innovation.

Research Methodology

This executive summary is built from a structured review of verified secondary sources, including global MS epidemiology references, regulatory agency communications, peer-reviewed clinical literature, health technology assessment trends, clinical guideline updates, and publicly available information from recognized neurology and MS organizations. The analysis emphasizes data consistency, clinical relevance, and market applicability across therapeutic, diagnostic, regional, and access dimensions.

The methodology combines epidemiological assessment, treatment landscape mapping, regional access evaluation, competitive trend interpretation, and technology impact analysis. Insights were synthesized to support executive decision-making while avoiding unsupported claims, speculative forecasts, market sizing, market share estimates, or unverified market assumptions.

Conclusion

The multiple sclerosis market is moving toward earlier intervention, higher-efficacy treatment, precision monitoring, and broader evidence requirements. While disease-modifying therapies have changed the outlook for many patients, major unmet needs remain in progressive disease, disability prevention, cognitive impairment, fatigue, equitable access, and long-term safety optimization.

For pharmaceutical and biotechnology executives, success will depend on delivering differentiated clinical value, validating outcomes in real-world populations, and building integrated access strategies across mature and emerging MS markets. Organizations that combine scientific innovation with patient-centered evidence and responsible AI adoption will be best positioned to support the next phase of MS care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Multiple Sclerosis Market, by Multiple Sclerosis Type

  • 7.1. Primary
  • 7.2. Secondary
  • 7.3. Relapsing
  • 7.4. Progressive-Relapsing

8. Multiple Sclerosis Market, by Treatment Type

  • 8.1. Disease-Modifying Therapies
    • 8.1.1. Injectable Therapies
    • 8.1.2. Oral Therapies
    • 8.1.3. Monoclonal Antibodies
  • 8.2. Symptomatic Treatments
  • 8.3. Acute Relapse Management

9. Multiple Sclerosis Market, by Mechanism of Action

  • 9.1. Immunomodulators
  • 9.2. Immunosuppressants
  • 9.3. Cell Depletion Therapies
  • 9.4. S1P Receptor Modulators
  • 9.5. Anti-adhesion Molecules

10. Multiple Sclerosis Market, by Route of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Intravenous

11. Multiple Sclerosis Market, by Drug Type

  • 11.1. Biologics
  • 11.2. Small Molecules

12. Multiple Sclerosis Market, by End User

  • 12.1. Hospitals
  • 12.2. Specialty Clinics
  • 12.3. Homecare Settings

13. Multiple Sclerosis Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Multiple Sclerosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Multiple Sclerosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Amgen Inc.
  • 17.2. AstraZeneca PLC
  • 17.3. Bayer AG
  • 17.4. Biogen Inc.
  • 17.5. Bristol-Myers Squibb Company
  • 17.6. Celgene Corporation
  • 17.7. F. Hoffmann-La Roche Ltd.
  • 17.8. Genentech, Inc.
  • 17.9. GlaxoSmithKline plc
  • 17.10. Horizon Therapeutics plc
  • 17.11. Johnson & Johnson
  • 17.12. Merck KGaA
  • 17.13. Mitsubishi Tanabe Pharma Corporation
  • 17.14. Novartis AG
  • 17.15. Otsuka Holdings Co., Ltd.
  • 17.16. Pfizer Inc.
  • 17.17. Sanofi S.A.
  • 17.18. Takeda Pharmaceutical Company Limited
  • 17.19. Teva Pharmaceutical Industries Ltd.
  • 17.20. TG Therapeutics, Inc.
  • 17.21. UCB S.A.
  • 17.22. Viela Bio, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLE SCLEROSIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MULTIPLE SCLEROSIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MULTIPLE SCLEROSIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRIMARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRIMARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRIMARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SECONDARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SECONDARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SECONDARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RELAPSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RELAPSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RELAPSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROGRESSIVE-RELAPSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROGRESSIVE-RELAPSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROGRESSIVE-RELAPSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DISEASE-MODIFYING THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DISEASE-MODIFYING THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DISEASE-MODIFYING THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE RELAPSE MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE RELAPSE MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE RELAPSE MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL DEPLETION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL DEPLETION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL DEPLETION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL S1P RECEPTOR MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL S1P RECEPTOR MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL S1P RECEPTOR MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-ADHESION MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-ADHESION MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-ADHESION MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GCC MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 139. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. G7 MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 163. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 205. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 253. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)